CATX
Perspective Therapeutics, Inc.
stockNYSEAMERICAN
the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning "short" or "close," because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or "seed" brachytherapy was pioneered in the 1960's as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.84 | 2026-11-06 | +12.26% | 2.323 |
| 1M | 2.27 | 2026-10-13 | -58.46% | 1.632 |
| 3M | 3.10 | 2026-08-13 | -69.58% | 1.849 |
| 6M | 3.82 | 2026-05-13 | -75.31% | 1.549 |
| 1Y | 2.07 | 2025-11-13 | -54.44% | 1.543 |
| 2Y | 9.93 | 2024-11-13 | -90.50% | — |
| 5Y | 3.53 | 2023-02-22 | -73.31% | 1.432 |
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) stock price today is $0.94, and today's volume is 2,317,383. CATX is up 11.942% today. The 30 day average volume is 3.52M. CATX market cap is $113.88M with 120.76M shares outstanding.